Company profile
Home - OxSonics Therapeutics
Oxsonics Limited is a UK company with status active founded in 2013 based in South East England.
Financial period: 1 Jul 2023 to 30 Jun 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
SH01 | Transaction MzUyOTUwNDY0NmFkaXF6a2N4
Published 30 Jun 2026 15:53
Last confirmation statement made up date
Last accounts made up date
SH10 | Transaction MzQ0NDQ3MDczNWFkaXF6a2N4 | Paper/PDF filed
Published 26 Nov 2024 10:34
MA | Transaction MzQ0MjM2Njk1NmFkaXF6a2N4 | Paper/PDF filed
Published 19 Nov 2024 10:43
RESOLUTIONS | Transaction WURGRUNYWkVhZGlxemtjeA | Paper/PDF filed
Published 19 Nov 2024 10:30
SH01 | Transaction MzQ0MjM5OTg2MGFkaXF6a2N4
Published 07 Nov 2024 04:52
SH08 | Transaction MzQzMTAxMzUwMGFkaXF6a2N4 | Paper/PDF filed
Published 08 Aug 2024 08:16
Company registered at Companies House
OxSonics has developed ultrasound technology to deliver drugs to treat cancers and chronic lower back pain.
OxSonics Therapeutics is developing an ultrasound device and injectable sonosensitive particles to enable the clinical translation of cavitation-enhanced oncological drug delivery.
The company successfully raised £1m of external investor capital and recently received a further £1.2m Primer Award from Innovate UK to develop a clinical prototype.
The company received a £2.5m Innovate UK early stage award in 2014 to enable pre-clinical development of the ultrasound device, associated ultrasound transducer and GMP manufacture of the sonosensitive particles.
1 Sep 2014 to 31 Aug 2017
The TSB Biomedical Catalyst Fund will be instrumental in enabling OxSonics Limited to develop a prototype of its first product, “SonoTran”, a low-cost therapeutic ultrasound device and associated consumables for the non-invasive targeted and enhanced delivery of cancer drugs to solid tumours. SonoTran has the capability to overcome the greatest challenge ...
